Poster Archives - WuXi Biology

Defining the Next Era of Cancer Therapeutics

Building on the momentum of AACR 2026, WuXi AppTec was honored to host an outstanding group of regional industry leaders...

PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC

Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...

Novel E3 Ligase to Support Targeted Protein Degradation

Targeted protein degradation (TPD) continues to expand the possibilities for next-generation therapeutics, and identifying novel E3 ligases remains an important...

Mechanistic Profiling of ADC-resistant Cancer Cell Lines

Antibody-drug conjugates (ADCs) have emerged as an important modality in targeted cancer therapy development. However, acquired resistance continues to limit...

Unveiling Mechanisms of MRTX1133 Resistance

Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with...

Development of the Venetoclax-Resistant AML Model

Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...

Biophysical Methods for Rapid Screening and Hit Validation

At DDC 2026, WuXi AppTec presented a poster showcasing our integrated discovery platform designed to accelerate the identification and validation...

Spectral Shift for Ultra-High-Throughput Binding Assays

High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...